The association was originally founded in 1948 as the Osaka Pharmaceutical Manufacturers Association (OPMA) and the name of OPMA was changed to the Kansai Pharmaceutical Industries Association (KPIA) on January 1st, 2018.
KPIA is a local organization aiming at enhancing common benefits for members and contributing to the realization of “Society of Health and Longevity” by making use of the strengths of Kansai*, and through strengthening joint collaboration, mutual understanding, and enlightenment of stakeholders including members, and through the sound development of the pharmaceutical and related industries.
The KPIA comprises over 300 pharmaceutical marketing authorization holders/ manufacturers and companies engaged in associated businesses, headquartered mainly in the Kansai Area. KPIA is a member of the Federation of Pharmaceutical Manufacturers’ Associations of JAPAN (FPMAJ) as a regional organization.
KPIA conducts its activities through four (4) committees and six (6) study groups and the secretariat, under the direction of the Board of Directors to address problems that operators in the pharmaceutical industries are facing. Specifically, KPIA keeps close contact and cooperation with, and promote mutual understanding with, the Ministry of Health, Labour and Welfare (MHLW), the Osaka Prefectural Government and other local authorities in the Kansai Area governing pharmaceutical industries to collect, examine, analyze, and compile information related to pharmaceutical-related laws and regulations and the pharmaceutical industries.
The results of these activities are communicated to members through seminars, newsletters, information network and other events and media to provide information and improve the knowledge of members. KPIA also makes various proposals related to pharmaceutical industries to the national and local governments and other public organizations.
*Strengths of Kansai for Pharmaceutical and Related Industries
・Integrated pharmaceutical and related industries typified by Dosho-Machi
・Integrated manufacturers having creative and advanced technologies in the variety of fields
・Consolidated presence of universities and research institutes related life science field
・Consolidated science and technology at the highest international level for creating new drugs
・Consolidated agencies for supporting and consulting drug discovery performed by academia and industry
・Proactive initiatives by local government for promotion of pharmaceutical and related industries
・Regions having a long history for gathering people, goods and information, and for interacting each other with Asia, Europe and America
・Presence of international distribution centers for import-export logistics such as Kansai International Airport
(Including, but not limited to the above)